Life Molecular Imaging (LMI) is a German molecular imaging company specializing in the development of positron emission tomography (PET) tracers for neurodegenerative diseases. Founded in 2013 and headquartered in Berlin, Germany, LMI focuses on developing novel radiopharmaceuticals for early diagnosis and monitoring of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[1].
The company became a wholly-owned subsidiary of Lantheus Holdings in 2024, strengthening its commercial and development capabilities[2].
| Attribute | Value |
|---|---|
| Founded | 2013 |
| Headquarters | Berlin, Germany |
| Parent Company | Lantheus Holdings |
| Focus | PET imaging tracers |
| Status | Acquired by Lantheus (2024) |
| Product | Target | Status |
|---|---|---|
| Neuraceq® (Florbetaben F-18) | Beta-amyloid plaques | FDA approved (2014) |
Neuraceq® is an FDA-approved PET tracer for estimating beta amyloid neuritic plaque density in adult patients with cognitive impairment being evaluated for Alzheimer's disease[1:1].
| Tracer | Target | Stage | Indication |
|---|---|---|---|
| LMI 119 | Tau protein | Phase 2 | Alzheimer's disease, PSP |
LMI 119 is a next-generation tau PET tracer in clinical development for Alzheimer's disease and progressive supranuclear palsy (PSP). Tau pathology correlates strongly with cognitive decline in these conditions[1:2].
| Tracer | Target | Stage | Indication |
|---|---|---|---|
| LMI 104 | Alpha-synuclein | Preclinical | Parkinson's disease, DLB |
LMI 104 targets alpha-synuclein aggregation, the hallmark pathology of Parkinson's disease and dementia with Lewy bodies (DLB). Currently in preclinical development[1:3].
| Program | Target | Application |
|---|---|---|
| MAO-B Imaging | Monoamine oxidase B | Parkinson's disease |
| Cardiac Amyloid | Amyloid transthyretin | Cardiac amyloidosis |
| Partner | Focus Area | Type |
|---|---|---|
| AC Immune | Tau PET tracer development | Co-development |
| Roche | Diagnostic development | Commercialization |
| Lantheus Holdings | Commercial distribution | Acquisition (2024) |
Life Molecular Imaging maintains active research collaborations with:
LMI is positioned as a leader in neurodegenerative PET imaging, with:
Life Molecular Imaging Ltd. Corporate Pipeline and Products. 2026. ↩︎ ↩︎ ↩︎ ↩︎
Lantheus Holdings. Lantheus Acquires Life Molecular Imaging. 2026. ↩︎